Enteroviruses in the early 21st century: New manifestations and challenges

Current Opinion in Pediatrics

Volumn 28, Issue 1, 2016, Pages 107-113

  Lugo, Debra ^a   Krogstad, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

enterovirus treatment; enterovirus D68; hand foot and mouth disease; pleconaril; poliovirus eradication

Indexed keywords

AMILORIDE; FLUOXETINE; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; MEFLOQUINE; PIRODAVIR; PLECONARIL; POLIOMYELITIS VACCINE; VAPENDAVIR; VIRUS VACCINE;

ACUTE FLACCID MYELITIS; ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; COXSACKIEVIRUS B1; ENTEROVIRUS; ENTEROVIRUS D68; ENTEROVIRUS INFECTION; EPIDEMIC; HAND FOOT AND MOUTH DISEASE; HUMAN; MYELITIS; NEUROLOGIC DISEASE; NEWBORN DISEASE; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; VACCINATION; VIRUS CLASSIFICATION; VIRUS MYOCARDITIS; VIRUS STRAIN; COMMUNICABLE DISEASES, EMERGING; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B; ENTEROVIRUS INFECTIONS; HAND, FOOT AND MOUTH DISEASE; MYOCARDITIS; NEWBORN; VIROLOGY;

COMMUNICABLE DISEASES, EMERGING; COXSACKIEVIRUS INFECTIONS; DISEASE OUTBREAKS; ENTEROVIRUS B, HUMAN; ENTEROVIRUS INFECTIONS; HAND, FOOT AND MOUTH DISEASE; HUMANS; INFANT, NEWBORN; MYELITIS; MYOCARDITIS; POLIOMYELITIS; VIRAL VACCINES;

EID: 84954028004     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000303     Document Type: Review

References (51)

1. Enders JF. Observations on certain viruses causing exanthematous diseases in man. Am J Med Sci 1956; 231:622-637.
2. Neva FA, Feemster RF, Gorbach IJ. Clinical and epidemiological features of an usual epidemic exanthem. J Am Med Assoc 1954; 155:544-548.
3. McMinn P, Stratov I, Nagarajan L, et al. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001; 32:236-242.
4. McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002; 26:91-107.
5. Ma E, Chan KC, Cheng P, et al. The enterovirus 71 epidemic in 2008: public health implications for Hong Kong. Int J Infect Dis 2010; 14:e775-780.
6. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-935.
7. Huang CC, Liu CC, Chang YC, et al. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999; 341:936-942.
8. Chen KT, Chang HL, Wang ST, et al. Epidemiologic features of hand-footmouth disease and herpangina caused by enterovirus 71 in Taiwan. Pediatrics 2007; 120:e244-e252.
9. Lu CY, Lee CY, Kao CL, et al. Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. J Med Virol 2002; 67:217-223.
10. Gau SS, Chang LY, Huang LM, et al. Attention-deficit/hyperactivity-related symptoms among children with enterovirus 71 infection of the central nervous system. Pediatrics 2008; 122:e452-e458.
11. Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis 2014; 14:308-318.
12. Centers for Disease Control and Prevention. Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6-Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep 2012; 61:213-214.
13. Bian L, Wang Y, Yao X, et al. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther 2015; 13:1061-1071.
14. Mathes EF, Oza V, Frieden IJ, et al. 'Eczema coxsackium' and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132:e149-e157.
15. Khetsuriani N, Lamonte A, Oberste MS, et al. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States. Pediatr Infect Dis J 2006; 25:889-893.
16. Verma NA, Zheng XT, Harris MU, et al. Outbreak of life-threatening coxsackievirus B1 myocarditis in neonates. Clin Infect Dis 2009; 49:759-763.
17. Wikswo ME, Khetsuriani N, Fowlkes AL, et al. Increased activity of Coxsackievirus B1 strains associated with severe disease among young infants in the United States. Clin Infect Dis 2009; 49:e44-e51.
18. Centers for Disease Control and Prevention. Nonpolio enterovirus and human parechovirus surveillance: United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2010; 59:1577-1580.
19. Abedi GR, Watson JT, Pham H, et al. Enterovirus and human parechovirus surveillance: United States. MMWR Morb Mortal Wkly Rep 2015; 64:940-943.
20. Wassilak SG, Oberste MS, Tangermann RH, et al. Progress toward global interruption of wild poliovirus transmission, 2010-2013, and tackling the challenges to complete eradication. J Infect Dis 2014; 210 (Suppl 1):S5-S15.
21. Michael CA, Ogbuanu IU, Storms AD, et al. An assessment of the reasons for oral poliovirus vaccine refusals in northern Nigeria. J Infect Dis 2014; 210 (Suppl 1):S125-S130.
22. Simpson DM, Sadr-Azodi N, Mashal T, et al. Polio eradication initiative in Afghanistan. J Infect Dis 2014; 210 (Suppl 1):S162-S172.
23. Burns CC, Shaw J, Jorba J, et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013; 87:4907-4922.
24. Polio Eradication & Endgame Midterm Review 2015. Edited by; 2015. Polio Eradication & Endgame Midterm Review.
25. Tokarz R, Hirschberg DL, Sameroff S, et al. Genomic analysis of two novel human enterovirus Cgenotypes found in respiratory samples from Peru. J Gen Virol 2013; 94:120-127.
26. Todd A, Taylor S, Huang QS. Identification of Enterovirus C105 for the first time in New Zealand. Western Pac Surveill Response J 2015; 6:60-62.
27. Piralla A, Daleno C, Girello A, et al. Circulation of two Enterovirus C105 (EVC105) lineages in Europe and Africa. J Gen Virol 2015; 96:1374-1379.
28. Bassey BE, Gasasira A, Mitula P, et al. Surveillance of acute flaccid paralysis in Akwa Ibom State, Nigeria 2004-2009. Pan Afr Med J 2011; 9:32.
29. Bingjun T, Yoshida H, Yan W, et al. Molecular typing and epidemiology of nonpolio enteroviruses isolated from Yunnan Province, the People's Republic of China. J Med Virol 2008; 80:670-679.
30. Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 1967; 85:297-310.
31. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, et al. Enterovirus surveillance: United States, 1970-2005. MMWR Surveill Summ 2006; 55:1-20.
32. Centers for Disease Control and Prevention (CDC). Clusters of acute respiratory illness associated with human enterovirus 68: Asia, Europe, and United States, 2008-2010. MMWR Morb Mortal Wkly Rep 2011; 60:1301-1304.
33. Furuse Y, Chaimongkol N, Okamoto M, et al. Molecular epidemiology of enterovirus d68 from 2013 to 2014 in Philippines. J Clin Microbiol 2015; 53:1015-1018.
34. Messacar K, Abzug MJ, Dominguez SR. 2014 outbreak of enterovirus D68 in North America. J Med Virol 2015; doi: 10.1002/jmv.24410. [Epub ahead of print]
35. Schuster JE, Miller JO, Selvarangan R, et al. Severe enterovirus 68 respiratory illness in children requiring intensive care management. J Clin Virol 2015; 70:77-82.
36. Messacar K, Schreiner TL, Maloney JA, et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 2015; 385:1662-1671.
37. Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995; 20:1201-1206.
38. Abzug MJ. The enteroviruses: problems in need of treatments. J Infect 2014; 68 (Suppl 1):S108-S114.
39. Zhang Y, Moore DD, Nix WA, et al. Neutralization of Enterovirus D68 isolated from the 2014 US outbreak by commercial intravenous immune globulin products. J Clin Virol 2015; 69:172-175.
40. McKinlay MA, Collett MS, Hincks JR, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis 2014; 210 (Suppl 1):S447-S453.
41. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36:1523-1532.
42. Abzug MJ, Michaels MG, Wald E, et al. A Randomized, double-blind, placebocontrolled trial of pleconaril for the treatment of neonates with enterovirus sepsis. J Pediatric Infect Dis Soc 2015; doi: 10.1093/jpids/piv015. [Epub ahead of print]
43. Bernard A, Lacroix C, Cabiddu MG, et al. Exploration of the antienterovirus activity of a series of pleconaril/pirodavir-like compounds. Antivir Chem Chemother 2015; doi: 10.1177/2040206615589035. [Epub ahead of print]
44. Rhoden E, Zhang M, Nix WA, et al. In vitro efficacy of antiviral compounds against enterovirus D68. Antimicrob Agents Chemother 2015; 59:7779-7781.
45. Ulferts R, van der Linden L, Thibaut HJ, et al. Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. Antimicrob Agents Chemother 2013; 57:1952-1956.
46. Zuo J, Quinn KK, Kye S, et al. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother 2012; 56:4838-4844.
47. Tyler KL. Rationale for the evaluation of fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis. JAMA Neurol 2015; 72:493-494.
48. Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855-1862.
49. Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 2007; 81:9386-9395.
50. Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-790.
51. Li JX, Song YF, Wang L, et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines 2016; 15:129-137.